Skip to main content
Top
Published in: Diabetologia 8/2011

01-08-2011 | Article

Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

Authors: L. Govan, O. Wu, A. Briggs, H. M. Colhoun, J. A. McKnight, A. D. Morris, D. W. M. Pearson, J. R. Petrie, N. Sattar, S. H. Wild, R. S. Lindsay, on behalf of the Scottish Diabetes Research Network Epidemiology Group

Published in: Diabetologia | Issue 8/2011

Login to get access

Abstract

Aims/hypothesis

The rising prevalence of diabetes worldwide has increased interest in the cost of diabetes. Inpatient costs for all people with diabetes in Scotland were investigated.

Methods

The Scottish Care Information—Diabetes Collaboration (SCI-DC), a real-time clinical information system of almost all diagnosed cases of diabetes in Scotland, UK, was linked to data on all hospital admissions for people with diabetes. Inpatient stay costs were estimated using the 2007–2008 Scottish National Tariff. The probability of hospital admission and total annual cost of admissions were estimated in relation to age, sex, type of diabetes, history of vascular admission, HbA1c, creatinine, body mass index and diabetes duration.

Results

In Scotland during 2005–2007, 24,750 people with type 1 and 195,433 people with type 2 diabetes were identified, accounting for approximately 4.3% of the total Scottish population (5.1 million). The estimated total annual cost of admissions for all people diagnosed with type 1 and type 2 diabetes was £26 million and £275 million, respectively, approximately 12% of the total Scottish inpatient expenditure (£2.4 billion). Sex, increasing age, serum creatinine, previous vascular history and HbA1c (the latter differentially in type 1 and type 2) were all associated with likelihood and total annual cost of admission.

Conclusions/interpretation

Diabetes inpatient expenditure accounted for 12% of the total Scottish inpatient expenditure, whilst people with diabetes account for 4.3% of the population. Of the modifiable risk factors, HbA1c was the most important driver of cost in type 1 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jönsson B, CODE-2 Advisory Board (2002) Revealing the cost of type II diabetes in Europe. Diabetologia 45:S5–S12PubMedCrossRef Jönsson B, CODE-2 Advisory Board (2002) Revealing the cost of type II diabetes in Europe. Diabetologia 45:S5–S12PubMedCrossRef
2.
go back to reference Nolan JJ, O'Halloran D, McKenna TJ, Firth R, Redmond S (2006) The cost of treating type 2 diabetes (CODEIRE). Ir Med J 99:307–310PubMed Nolan JJ, O'Halloran D, McKenna TJ, Firth R, Redmond S (2006) The cost of treating type 2 diabetes (CODEIRE). Ir Med J 99:307–310PubMed
3.
go back to reference American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596–615CrossRef American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596–615CrossRef
4.
go back to reference Morgan CL, Peters JR, Dixon S, Currie CJ (2010) Estimated costs of acute hospital care for people with diabetes in the United Kingdom: a routine record linkage study in a large region. Diabet Med 27:1066–1073PubMedCrossRef Morgan CL, Peters JR, Dixon S, Currie CJ (2010) Estimated costs of acute hospital care for people with diabetes in the United Kingdom: a routine record linkage study in a large region. Diabet Med 27:1066–1073PubMedCrossRef
5.
go back to reference Gray A, Fenn P, McGuire A (1995) The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 12:1068–1076PubMedCrossRef Gray A, Fenn P, McGuire A (1995) The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 12:1068–1076PubMedCrossRef
6.
go back to reference Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765 (Erratum 52:2469)PubMedCrossRef Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765 (Erratum 52:2469)PubMedCrossRef
11.
go back to reference Briggs A (1998) Given the distributional nature of costing and resource utilisation, is it more approriate to use median or mean descriptive statistics? J Health Serv Res Policy 3:127 Briggs A (1998) Given the distributional nature of costing and resource utilisation, is it more approriate to use median or mean descriptive statistics? J Health Serv Res Policy 3:127
12.
go back to reference Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New YorkCrossRef Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New YorkCrossRef
13.
go back to reference Prospective Studies Collaboration (2009) Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096CrossRef Prospective Studies Collaboration (2009) Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096CrossRef
14.
go back to reference Wild S, SDRN Epidemiology Group (2010) Body mass index and mortality among people with diabetes: a retrospective population based cohort study. American Diabetes Association 0328-OR (Abstract) Wild S, SDRN Epidemiology Group (2010) Body mass index and mortality among people with diabetes: a retrospective population based cohort study. American Diabetes Association 0328-OR (Abstract)
15.
go back to reference Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef
16.
go back to reference Leslie PJ, Patrick AW, Hepburn DA, Scougal IJ, Frier BM (1992) Hospital in-patient statistics underestimate the morbidity associated with diabetes mellitus. Diabet Med 9:379–385PubMedCrossRef Leslie PJ, Patrick AW, Hepburn DA, Scougal IJ, Frier BM (1992) Hospital in-patient statistics underestimate the morbidity associated with diabetes mellitus. Diabet Med 9:379–385PubMedCrossRef
18.
go back to reference Laditka SB, Mastanduno MP, Laditka JN (2001) Health care use of individuals with diabetes in an employer-based insurance population. Arch Intern Med 161:1301–1308PubMedCrossRef Laditka SB, Mastanduno MP, Laditka JN (2001) Health care use of individuals with diabetes in an employer-based insurance population. Arch Intern Med 161:1301–1308PubMedCrossRef
20.
go back to reference Holt TA, Stables D, Hippisley-Cox J, O'Hanlon S, Majeed A (2008) Identifying undiagnosed diabetes: cross-sectional survey of 3.6 million patients' electronic records. Br J Gen Pract 58:192–196PubMedCrossRef Holt TA, Stables D, Hippisley-Cox J, O'Hanlon S, Majeed A (2008) Identifying undiagnosed diabetes: cross-sectional survey of 3.6 million patients' electronic records. Br J Gen Pract 58:192–196PubMedCrossRef
Metadata
Title
Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
Authors
L. Govan
O. Wu
A. Briggs
H. M. Colhoun
J. A. McKnight
A. D. Morris
D. W. M. Pearson
J. R. Petrie
N. Sattar
S. H. Wild
R. S. Lindsay
on behalf of the Scottish Diabetes Research Network Epidemiology Group
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2176-7

Other articles of this Issue 8/2011

Diabetologia 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.